C12N 2770/00033
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/00033 (Use of viral protein as therapeutic agent other than vaccine) appears on 21 US grants and 29 published applications in this corpus.
Search patents in C12N- Granted patents
- 21
- Published applications
- 29
- Assignees
- 5
- Inventors
- 12
- Latest grant
- 25 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 2 |
| 2015 | 0 | 0 |
| 2016 | 0 | 3 |
| 2017 | 2 | 2 |
| 2018 | 3 | 2 |
| 2019 | 2 | 3 |
| 2020 | 2 | 3 |
| 2021 | 4 | 2 |
| 2022 | 1 | 3 |
| 2023 | 2 | 2 |
| 2024 | 4 | 2 |
| 2025 | 1 | 3 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- PIC1 inhibition of myeloperoxidase oxidative activity in an animal model25 Mar 2025US 12,257,290 B2Realta Holdings, LLC
- RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci20 Aug 2024US 12,065,668 B2The General Hospital Corporation
- MUC16 specific chimeric antigen receptors and uses thereof14 May 2024US 11,981,746 B2Precigen, Inc.
- MUC16 specific chimeric antigen receptors and uses thereof7 May 2024US 11,976,134 B2Precigen, Inc.
- Increasing specificity for RNA-guided genome editing5 Mar 2024US 11,920,152 B2The General Hospital Corporation
- Pic1 inhibition of myeloperoxidase oxidative activity in an animal model10 Sep 2026US 2026/0263566 A1Realta Holdings, LLC
- Pic1 inhibition of myeloperoxidase oxidative activity in an animal model22 Jan 2026US 2026/0021164 A1Realta Holdings, LLC
- Human t-cell lymphotropic virus type 1 targeting proteins and methods of use13 Nov 2025US 2025/0346636 A1City of Hope
- Pic1 inhibition of myeloperoxidase oxidative activity in an animal model5 Jun 2025US 2025/0177492 A1Realta Holdings, LLC
- RNA-Guided Targeting of Genetic and Epigenomic Regulatory Proteins to Specific Genomic Loci30 Jan 2025US 2025/0034597 A1The General Hospital Corporation
Most cited
By later US patents
- Increasing specificity for RNA-guided genome editing95US 9,885,033 B2The General Hospital Corporation · 2018
- Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing87US 9,567,604 B2The General Hospital Corporation · 2017
- Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing85US 9,567,603 B2The General Hospital Corporation · 2017
- Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing43US 10,415,059 B2The General Hospital Corporation · 2019
- Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing39US 10,119,133 B2The General Hospital Corporation · 2018